China’s CoronaVac safe for use in children: study
The Hindu
Higher dose induced neutralising antibody responses in trials of 3-17 year-olds
A higher dose of the Chinese vaccine CoronaVac was “well tolerated and safe, and induced neutralising antibody responses in children and adolescents aged 3-17 years”, a study in the recent edition of the peer-reviewed journal Lancet Infectious Diseases has stated. The seroconversion rates of neutralising antibodies in children and adolescents with two different doses were over 96% after a double-dose vaccination, the paper reported. The double-blind randomised, controlled, phase 1/2 clinical trial of CoronaVac (inactivated SARS-CoV-2), in healthy children and adolescents aged 3-17 years was conducted at the Hebei Provincial Center for Disease Control and Prevention in Zanhuang (Hebei, China).More Related News